Elsevier

Atherosclerosis

Volume 246, March 2016, Pages 243-250
Atherosclerosis

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey

https://doi.org/10.1016/j.atherosclerosis.2016.01.018Get rights and content

Highlights

  • Management of dyslipidaemia in CHD patients in Europe has improved over the last ten years.

  • A large majority of CHD patients with dyslipidaemia is still inadequately treated.

  • Many CHD patients on lipid-lowering therapy are not reaching the treatment goals for lipids according to the guidelines.

  • A potential exists throughout Europe to reduce CHD mortality and morbidity rates through better treatment of dyslipidaemia.

Abstract

Objective

Since dyslipidaemia is one of the most important risk factors for coronary heart disease (CHD), lowering of LDL-cholesterol (LDL-C) causes significant reduction in morbidity and mortality, particularly in patients with established CHD. The aim of this survey was to assess how statins were prescribed in CHD patients at discharge after a coronary event from hospitals throughout Europe and how the intake of these drugs was reported by the patients when they were seen more than one year later in relationship with their achieved LDL-C levels.

Methods

6648 CHD patients' data from centres in 24 European countries were gathered using standardized methods. Lipid measurements were performed in one central laboratory. Patients were divided in three groups: high-intensity statin therapy, moderate or low intensity statin therapy and no statin therapy at all.

Results

90.4% CHD patients were on statin therapy at the time of discharge from the hospital which decreased to 86% one year later. Only 37.6% of these patients were prescribed a high-intensity statin at discharge which even decreased to 32.7% later. In only 6 countries (all of them high-income countries) the number of patients on a high-intensity statin therapy increased substantially after the hospital discharge. It is worrying that statin therapy was discontinued in 11.6% and that only 19.3% of all CHD patients achieved target values of LDL-C < 1.8 mmol/L at the time of interview.

Conclusions

Too many CHD patients with dyslipidaemia are still inadequately treated and most of these patients on statin therapy are not achieving the treatment targets. Therapeutic control of LDL-C is clearly related to the intensity of lipid lowering drug regimen after the CHD event indicating that a considerable potential still exists throughout Europe to reduce CHD mortality and morbidity rates through more efficient LDL-C lowering.

Introduction

It is well known that dyslipidaemia is one of the most important causal risk factors for coronary heart disease (CHD) [1], [2]. Although the use of lipid-lowering drugs in primary prevention is less cost-effective, at least to some extent in subjects at low total cardiovascular (CV) risk, there are absolutely no doubts concerning the imperative use of lipid lowering drugs, more precisely statins, for secondary prevention, i.e. in patients with established CHD. Randomized controlled trials have clearly proven that LDL-cholesterol (LDL-C) lowering with statins, can reduce the risk of recurrent cardiovascular events in these patients [3]. It has also been shown that further lowering of LDL-C beyond the levels that can be achieved with less potent statins or at a lower dose of a given statin, is associated with more CHD prevention [3], [4].

Therefore the US guidelines recommend to use high-intensity statin therapy in coronary patients in order to achieve a lowering of LDL-C by at least 50% [5]. European guidelines recommend a LDL-C goal of <1.8 mmol/L (<70 mg/dL) or at least 50% reduction of LDL-C in patients with documented CHD [2], [6]. Unlike the US guidelines, the European guidelines and a number of European reviews recommended combined lipid-lowering treatment even before the results of IMPROVE-IT trial were published [7], [8]. The results of the IMPROVE-IT trial clearly showed that significantly more CHD patients treated with a combination of a statin and ezetimibe can meet LDL-C goals than patients treated with statin alone; this was also associated with improved outcomes after multivariable adjustment [9].

The objectives of this study in the hospital arm of the EUROASPIRE IV survey were to examine how lipid lowering drugs were prescribed in CHD patients at discharge from hospital throughout Europe and how the intake of these drugs was reported by the patients when they were seen for a standardized interview at least 6 months later. Possible correlates of the differences between what was prescribed at discharge versus what was reported at the interview were examined. A comparison is also made of the proportions of patients at goal for LDL-C (<1.8 mmol) versus those at goal for non-HDL-C (<2.6 mmol/L).

Section snippets

Materials and methods

The design, methodology and main results of the EUROASPIRE IV survey have been described elsewhere [10]. EUROASPIRE IV was a cross-sectional survey conducted at 79 centres in 24 European countries during May 2012 to April 2013 using standardised methods and the same equipment in every centre. In a defined geographical area in each of these countries, consecutive male or female patients aged 18–80 years were identified from hospital admission and discharge lists or diagnostic registers by the

Results

A statistically significant shift in the prescription of statin therapy was observed between hospital discharge and interview (P < 0.0001). From a total of 6648 CHD patients 9.6% were not on a statin therapy at the time of discharge from the hospital; this increased to 14% at interview; 37.6% of the patients were prescribed a high-intensity LDL-C lowering therapy at discharge which decreased to 32.7% at the time of the interview. Table 1 presents the results regarding lipid lowering drug

Discussion

The results of the EUROASPIRE IV survey concerning lipid lowering therapy in CHD patients show that despite the clear evidence of the benefits of lipid-lowering treatment with statins in secondary prevention, many coronary patients with dyslipidaemia are still inadequately treated and a significant number of patients on lipid-lowering therapy is still not reaching the LDL-C treatment goals. According to these results every tenth patient in European centres has been discharged from the hospital

Funding

The EUROASPIRE IV survey was supported by unrestricted educational grants to the European Society of Cardiology from Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, F. Hoffman–La Roche and Merck, Sharp & Dohme. The sponsors of the EUROASPIRE surveys had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript. .

Acknowledgements

The EUROASPIRE IV survey was carried out under the auspices of the European Society of Cardiology, EURObservational Research Programme. EUROASPIRE Study Group is grateful to all the hospitals in which the study was carried out. Their administrative staff, physicians, nurses and other personnel helped us in many ways and we very much appreciate this. We are also grateful to the patients who participated in the study.

References (38)

  • C. Baigent et al.

    Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

    Lancet

    (2010)
  • Reiner Ž

    Statins in the primary prevention of cardiovascular disease

    Nat. Rev. Cardiol.

    (2013)
  • N.J. Stone et al.

    2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American heart association task force on practice guidelines

    Circulation

    (2014)
  • Catapano AL. Reiner Ž et al.

    ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis society (EAS)

    Eur. Heart J.

    (2011)
  • Reiner Ž

    Combined therapy in the treatment of dyslipidemia

    Fundam. Clin. Pharmacol.

    (2010)
  • Reiner Ž

    Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update

    Nutr. Metab. Cardiovasc Dis.

    (2013)
  • E.A. Bohula et al.

    Achievement of dual low-density lipoprotein cholesterol and high-sensitivity c-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT

    Circulation

    (2015)
  • K. Kotseva et al.

    EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries

    Eur. J. Prev. Cardiol.

    (2015 Feb 16)
  • B. Monaldi et al.

    Adherence to statin treatment following a myocardial infarction: an Italian population-based survey

    Clin. Outcomes Res.

    (2015)
  • Cited by (173)

    • Statin therapy and sex hormones

      2023, Principles of Gender-Specific Medicine: Sex and Gender-Specific Biology in the Postgenomic Era
    View all citing articles on Scopus
    View full text